These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 14609361)
1. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation. Keam SJ; Scott LJ; Curran MP Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361 [TBL] [Abstract][Full Text] [Related]
2. Spotlight on verteporfin in subfoveal choroidal neovascularisation. Keam SJ; Scott LJ; Curran MP Drugs Aging; 2004; 21(3):203-9. PubMed ID: 14979737 [TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441 [TBL] [Abstract][Full Text] [Related]
4. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA; Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056 [TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Bressler NM; Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980 [TBL] [Abstract][Full Text] [Related]
6. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ; Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792 [TBL] [Abstract][Full Text] [Related]
7. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ; Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937 [TBL] [Abstract][Full Text] [Related]
8. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Verteporfin In Photodynamic Therapy Study Group Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929 [TBL] [Abstract][Full Text] [Related]
9. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Verteporfin Roundtable Participants Retina; 2005; 25(2):119-34. PubMed ID: 15689800 [TBL] [Abstract][Full Text] [Related]
10. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Fenton C; Perry CM Drugs Aging; 2006; 23(5):421-45. PubMed ID: 16823995 [TBL] [Abstract][Full Text] [Related]
11. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4. Pieramici DJ; Bressler SB; Koester JM; Bressler NM Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587 [TBL] [Abstract][Full Text] [Related]
12. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Japanese Age-Related Macular Degeneration Tial (JAT) Study Group Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215 [TBL] [Abstract][Full Text] [Related]
13. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. ; ; Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872 [TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Verteporfin in Photodynamic Therapy Study Group Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011 [TBL] [Abstract][Full Text] [Related]
15. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Sickenberg M; Schmidt-Erfurth U; Miller JW; Pournaras CJ; Zografos L; Piguet B; Donati G; Laqua H; Barbazetto I; Gragoudas ES; Lane AM; Birngruber R; van den Bergh H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM Arch Ophthalmol; 2000 Mar; 118(3):327-36. PubMed ID: 10721954 [TBL] [Abstract][Full Text] [Related]
16. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC; Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216 [TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation. Harding S Eye (Lond); 2001 Jun; 15(Pt 3):407-12. PubMed ID: 11450766 [TBL] [Abstract][Full Text] [Related]
19. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Bessler NM; Retina; 2004 Aug; 24(4):512-20. PubMed ID: 15300071 [TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]